Health Economics in Breast Cancer

Beckmann, Matthias W.; Lux, Michael P.

doi:10.1159/000346882

Cited by 2 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer care is a very costly endeavor, especially now that patients tend to survive longer, thus prolonging the treatment period (39). Breast cancer, specifically, is the main cause of cancer-related mortality among women throughout the world.…”

Section: Breast Cancermentioning

confidence: 99%

“…When conducting a socio-economic analysis of combination therapies, it is crucial to adopt a farreaching view on their financial impact. For example, although offering an adjuvant therapy implies additional immediate costs, on the long term such a regimen (if optimal) can be cost-saving, because it has the potential to inhibit metastases and limit recurrences of tumor (39).…”

Section: Pharmacologic Treatment Of Breast Cancer Includes a Large Number Of Anticancer Agents With Distinct Mechanisms Of Action And Varmentioning

confidence: 99%

See 1 more Smart Citation

Combination Therapy of Anti-Tau and Anti-Amyloid Drugs for Disease Modification in Early-Stage Alzheimer’s Disease: Socio-Economic Considerations Modeled on Treatments for Tuberculosis, Hiv/Aids and Breast Cancer

Tomaszewski

Gauthier

Wimo³

et al. 2015

J Prev Alz Dis

View full text Add to dashboard Cite

Current drugs for treatment of mild to severe dementia of the Alzheimer’s type include cholinesterase inhibitors and the NMDA non-competitive receptor antagonist memantine. There is controversy as to the additive benefit of these symptomatic drugs, and their effects are clinically modest. Patients with Alzheimer’s disease (AD) are known to have characteristic pathology, including senile plaques with amyloid beta-protein aggregates and neurofibrillary tangles with assembled tau proteins, which start in the hippocampus and spread to neighboring areas. Amyloid and tau modifying drugs are under clinical testing. Based on this pathophysiology, it is crucial to investigate whether anti-amyloid and anti-tau combined therapy would show efficacy in early stage of AD, beyond what could be achieved with anti-amyloid or anti-tau monotherapy. It is equally important to consider the socio-economic implications of such a combination therapy, if effective. We hypothesize that the high costs of combination therapy for early-stage AD patients will require societal and public health initiatives to ensure universal access to AD treatment. In order to better predict these socio-economic implications, we summarize the management of other combination therapies used for tuberculosis, HIV/AIDS, and breast cancer, based on a database search of PubMed and other relevant sources. We put forward a framework for testing a potential anti-amyloid and anti-tau disease modifying combination therapy for early-stage AD patients and present an analysis of the socio-economic implications of such a combination therapy.

show abstract

Section: Breast Cancermentioning

confidence: 99%

Section: Pharmacologic Treatment Of Breast Cancer Includes a Large Number Of Anticancer Agents With Distinct Mechanisms Of Action And Varmentioning

confidence: 99%